Skip to content
naulon
Not checkedNot checked for notices yet.

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram and 20 more

iScience · 2021

doi:10.1016/j.isci.2021.102298 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Summary: We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP-grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety were determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats, and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers (NAb), at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation contains TLR7/8 agonist adjuvant-induced Th1-biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2-specific IFN-γ+ CD4+ T lymphocyte response. Our results support further development for phase I/II clinical trials in humans.

Abstract licence: CC BY-NC

References45

  1. 11.
  2. 14.
  3. 18.
  4. 26.
  5. 35.

35 more references, whose wording the paper’s licence keeps private.

All 45 references

Cited by papers we hold2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.